Search results
Showing 61 to 75 of 1338 results for 0
Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)
Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.
Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention
In development [GID-IPG10391] Expected publication date: 05 February 2025
In development [GID-IPG10392] Expected publication date: 05 February 2025
In development [GID-IPG10268] Expected publication date: 08 January 2025
Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.
In development [GID-IPG10267] Expected publication date: 14 August 2025
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Awaiting development [GID-TA10393] Expected publication date: TBC
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.
Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.
View recommendations for MTG48Show all sections
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)